COMMUNITY-ACQUIRED PNEUMONIA IN UGANDAN ADULTS: SHORT-TERM PARENTERAL AMPICILLIN THERAPY FOR BACTERIAL PNEUMONIA

HIROYUKI YOSHIMINE, KAZUNORI OISHI, FRANCIS MUBIRU, HAWA NALWOGA, HIDEHIKO TAKAHASHI, HIDEAKI AMANO, PHILIP OMBASI, KIWAO WATANABE, MOSES JOLOBA, THOMAS AISU, KAMRUDDIN AHMED, MASAAKI SHIMADA, ROY MUGERWA, AND TSUYOSHI NAGATAKE

Department of Internal Medicine and Information and Reference Center, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan; Department of Medicine and Microbiology, Makerere University, Kampala, Uganda

Abstract. A hospital-based prospective study of 99 patients with community-acquired pneumonia (CAP) was carried out in Kampala, Uganda. We evaluated microbiological etiologies, clinical features and effectiveness of short-term parenteral ampicillin followed by oral amoxicillin for these patients in relation to HIV-status. We demonstrated a very high prevalence (75%) of HIV-1 infection. No significant difference was observed with respect to age, gender, prior antibiotic usage, symptoms, laboratory data or bacterial etiology between HIV-1-infected and HIV-uninfected CAP patients. Most strains of Streptococcus pneumoniae (n = 19) and Haemophilus influenzae (n = 8) isolated from HIV-1-infected patients were penicillin-resistant (95%) and β-lactamase producing (75%) strains, respectively. A high percentage of good clinical response was found in both HIV-1-infected (81%) and HIV-uninfected (86%) among 39 patients with CAP due to a defined bacterial pathogen. These data support the use of short-term parenteral ampicillin for patients with bacterial CAP irrespective of HIV-status.

INTRODUCTION

Acute respiratory infections commonly cause morbidity and mortality in tropical and developing countries.1 A changing pattern of these diseases has, however, been recognized especially in sub-Saharan Africa, where there is a high seroprevalence of HIV infection.2 Although the incidence of opportunistic infections in HIV-infected persons has decreased in industrialized countries following the initiation of antiretroviral therapy, the social and medical situation of HIV-infected persons in sub-Saharan Africa remains unchanged.3 The high HIV infection rate among patients with pneumonia or acute respiratory illness supports the hypothesis that HIV infection is an important risk factor for these diseases in these areas.4,5 A recent study in the United States demonstrated that bacterial pneumonia is more frequent in HIV-infected persons than HIV-uninfected persons, and the risk is highest among those with CD4 lymphocyte counts less than 200/μl.6 A substantial dysfunction of humoral immunity associated with HIV infection appears to predispose to bacterial pneumonia in these patients.7

Previous investigators have demonstrated that penicillin is cost-effective in the treatment of lobar pneumonia before the outbreak of HIV infection in Africa.8,9 A recent paper from India also emphasized the need for a cost-effective approach to treatment of CAP for example with the use of parenteral penicillin in developing countries.10 Moreover, Siegel and colleagues similarly demonstrated the cost-effectiveness of short-term parenteral therapy with cephalosporins for CAP in the US.11 On the other hand, two recent studies in Africa have demonstrated the etiologic diagnosis and outcome of patients with community-acquired pneumonia (CAP). These studies reported relatively low frequencies of HIV infection among these patients (8% in Ethiopia and 26% in Cameroon), but did not focus on the effectiveness of antibiotic treatment.12,13 Therefore, the clinical effectiveness of short-term parenteral therapy against bacterial CAP in HIV-infected and HIV-uninfected patients in HIV-endemic, developing countries is not well documented.

In this study, we evaluated the clinical and microbiological features of adult patients with CAP as well as the clinical effectiveness of short-term parenteral ampicillin followed by oral amoxicillin for bacterial CAP in Uganda, a country in which HIV-1 infection is very prevalent.

PATIENTS AND METHODS

Patients. Between November 1996 and March 1998, 99 patients admitted with CAP were enrolled by clinicians (F. M. and H. N.) at the Department of Medicine, Makerere Medical School, Kampala, Uganda, after written informed consent had been obtained from either the patient or the principal care giver. Inclusion criteria for this study were: (1) patients > 18 yrs of age with a putative diagnosis of pneumonia made within 24 hr of admission; (2) a new pulmonary infiltrate on chest radiograph; and (3) clinical observation of one major criterion (cough, sputum production, or temperature > 37.0°C) or one minor criterion (white blood cell count > 9,000/μl or a serum C-reactive protein (CRP, Wako Chemical Industries Ltd, Osaka, Japan) level > 1.0 mg/dl), according to previous reports.14,15 Patients in whom radiographic abnormalities were attributable to congestive heart failure or chronic underlying lung diseases were excluded. No antiretroviral therapy or HIV prophylactic treatments such as trimethoprim-sulfamethoxazole (TMP-SMZ) or isoniazid had been prescribed for the HIV-infected patients. Prior antibiotic usage was defined as any prescribed or self-administered antibiotics. The study protocol was reviewed and approved by the Ugandan National AIDS Research Committee and the National Council for Science and Technology of Uganda.

Microbiological examinations. Full evaluation included expectorated sputum for cytological screening (< 10 epithelial cells and > 25 polymorphonuclear cells per low power field), Gram’s staining of a smear, quantitative sputum culture employing rabbit blood agar after homogenization with N-acetylcysteine (Senju Pharmaceutical Co., Osaka, Japan).
as previously described. Acute phase and convalescent sera from patients were used for the antibody detection against *Chlamydia pneumoniae* (Hitachi Kasei Co. Ltd., Tokyo, Japan), *Legionella* species (Denka Seiken Co. Ltd., Tokyo, Japan), and *Mycobacterium pneumoniae* (Fuji Rebio Co. Ltd., Tokyo, Japan). Between 2 and 4 weeks after enrollment, convalescent sera were obtained and stored at −80 °C.

**Classification of etiologic diagnosis.** The criteria for etiologic diagnosis were 1) positive blood culture of bacterial pathogen; 2) a heavy growth of bacterial pathogen (> 10⁶ colony-forming units (cfu/ml) on sputum culture or a mild growth of bacterial pathogen (> 10⁵ cfu/ml) in which the Gram-staining of a smear revealed a predominant organism morphologically compatible with the culture result; 3) fourfold rise in an agglutination test for *M. pneumoniae*, in an ELISA titer of IgG for *C. pneumoniae*, or in an agglutination test for *Legionella* species; and 4) induced sputum revealing *Mycobacterium tuberculosis* only when *M. tuberculosis* was regarded to be attributable to CAP. When no specific microbiological diagnosis was made, the etiology was classified as unknown. No patients with associated conditions that predisposed to aspiration combined with a new infiltrate in a dependent pulmonary segment were noted.

**Clinical and laboratory examinations.** Within 24 hr of admission, a physician examined the patients and recorded the findings on standardized case record forms. Diagnostic examinations included a chest roentgenogram (PA view), complete blood count with differential, blood culture, and serum CRP. Hypoxemia, defined as arterial oxygen saturation < 90% was determined by oximetry (Nonin Medical, Inc., North Plymouth, MN) on the finger. HIV serostatus was determined for all the patients enrolled using particle agglutination (Fuji Rebio) and Western blot (Ortho Diagnostic Inc, Raritan, NJ). The CD4 and CD8 lymphocyte counts in the peripheral blood were examined by flow cytometry in each patient at the time of enrollment. This test was not performed for six patients (five HIV-1-infected, one HIV-uninfected).

**In vitro susceptibility test.** Minimum inhibitory concentrations (MICs) of penicillin G (Meiji Seika Kaisha Ltd, Tokyo, Japan), ampicillin (Meiji Seika Kaisha), sulfamicillin (Pfizer Pharmaceutical, Tokyo, Japan), cefuroxime (Nippon Glaxo, Tokyo, Japan), cefmenoxime (Takeda Chemical Industries, Osaka, Japan), erythromycin (Dainippon Pharmaceutical Co. Ltd, Osaka, Japan), minocycline (Lederle Japan Ltd, Tokyo, Japan), gentamicin (Schering-Plough, Tokyo, Japan), ampicillin (Meiji Seika Kaisha), and 8 strains of *Streptococcus pneumoniae* and 8 strains of *Haemophilus influenzae* isolated from patients with CAP were determined by the agar dilution methods as recommended by the Japanese Society of Chemotherapy.

**Treatment and clinical response.** A short-term regimen of parenteral ampicillin (1 gram twice a day) for 3 days followed by 1.5 gram per day of oral amoxicillin for 4 to 7 days were given as the standard therapy for enrolled patients with CAP. Anti-tuberculosis drugs consisting of rifampin, pyrazinamide, ethambutol and isoniazid were given after the standard therapy in cases of suspected *M. tuberculosis* infection who were positive on Ziehl-Neelsen stain of sputum.

Twelve (fifteen HIV-1-infected and five HIV-uninfected) patients withdrew from the study before evaluation of effectiveness of antimicrobial therapy. There was no difference in proportion of HIV-1 infection and gender, and in age between evaluated and withdrawn patients. The effectiveness of antimicrobial therapy consisting of parenteral ampicillin was evaluated on patients with identified pathogens using the following criteria: 1) good response if the initial findings of chest radiograph improved and one major criterion (cough, sputum production, fever) and one minor criterion (a white blood cell count reduced to less than 9,000/µl or a serum CRP value lowered to 50% or less of the previous value) improved; 2) poor response if the initial findings of chest radiograph worsened, or one major or minor criterion worsened. The patients were examined at the Department of Medicine, Makerere University at day 1, day 3, day 7, and day 14 after enrollment. The findings on clinical examination and laboratory data were recorded at each of these visits after the enrollment.

**Statistical analysis.** Statistical comparisons of categorical clinical variables were made by Chi-square analysis or by Fisher’s exact test, of CD4, CD8 lymphocyte count and the CD4/CD8 ratio were made by Mann-Whitney U test. The comparison of clinical effectiveness stratified by HIV-status was made by Fisher’s exact test. A P value of < 0.05 was considered significant.

**RESULTS**

Ninety-nine consecutive adult patients with CAP were evaluated. Among them 74 (75%) were HIV-1-infected and 25 (25%) were HIV-uninfected (Table 1). There was no significant difference in gender or age between these groups. The CD4 lymphocyte counts and the CD4/CD8 ratio in HIV-1-infected patients were significantly lower than those in HIV-uninfected (P < 0.0001). In contrast, the CD8 peripheral-blood lymphocyte counts in HIV-infected patients were significantly higher than those in HIV-uninfected (P < 0.0001). More than 50% of the HIV-1-infected and HIV-uninfected patients with CAP had high respiratory (> 30 / min) and heart rates (> 100 / min). More than 50% of the enrolled patients had hypoxemia, but did not receive oxygen therapy because of lack of facilities. Penicillin (21%) and TMP-SMZ (12%) were frequently noted as prior antibiotic use. The CD4 lymphocyte counts of the most (73%) of the HIV-1-infected patients were less than 400/µl (Figure 1). This finding suggests a close relationship between HIV infection and the incidence of CAP. Before treatment, there were no significant differences between HIV+ and HIV− patients with respect to demographic characteristics, age, gender, rate of prior antibiotic usage, respiratory and heart rate, or laboratory data including white blood cell counts, levels of hemoglobin, serum levels of CRP, the rate of hyp-
oxemia, and the rate of multilobar involvement and pleural effusion on chest radiograph.

At least one etiologic pathogen was identified in 48 cases (41 cases in HIV-1-infected and 7 cases in HIV-uninfected patients) among the enrolled patients (Table 2). The most common bacterial etiologies were *S. pneumoniae* (25 cases), *H. influenzae* (10 cases), *Moraxella catarrhalis* (8 cases), *Staphylococcus aureus* (5 cases) and *Klebsiella pneumoniae* (5 cases). Blood culture was positive in 6 cases: *S. pneumoniae* (4 cases) and *Enterobacter cloacae* (1 case) were found in HIV-1-infected patients; *S. pneumoniae* (1 case) was found in an HIV-uninfected patient. Two cases of CAP were found to be attributable to *M. tuberculosis*, although we identified this pathogen in 5 cases. Convalescent sera were obtained from all 99 patients. No four-fold rise in antibodies specific for *M. pneumoniae*, *C. pneumoniae*, and *Legionella* species was observed. Subsequently, 55 and 7 causative pathogens were identified in HIV-1-infected and HIV-uninfected patients, respectively. No difference was noted with respect to the isolated pathogens between HIV-1-infected and HIV-uninfected patients, except for *M. tuberculosis* in two HIV-1-infected patients. Polymicrobial infections were observed in 13 cases of HIV-1-infected patients and one case of HIV-uninfected patients. The mean (± SD) of CD4 lymphocyte counts (µl) at diagnosis by bacterial etiology in HIV-1-infected patients were 260 ± 212 in *S. pneumoniae* (22 cases), 381 ± 449 in *H. influenzae* (9 cases), 405 ± 291 in *M. catarrhalis* (8 cases), 127 ± 127 in *S. aureus* (4 cases), and 415 ± 270 in *K. pneumoniae* (3 case), respectively. The mean of CD4 lymphocytes counts/µl in HIV-1-infected patients with CAP due to *M. tuberculosis* (2 cases) was 39.

The MIC<sub>90</sub> and the MIC<sub>90</sub> of penicillin G against 19 strains of *S. pneumoniae* were 0.78 µg/ml and 1.56 µg/ml, respectively (Table 3). Most (18/19; 95%) of the isolated strains of *S. pneumoniae*, therefore, were resistant to penicillin (15 were PISP and 3 were PRSP). The MIC<sub>90</sub> and the MIC<sub>90</sub> of amoxicillin against *S. pneumoniae* were 0.20 µg/ml and 0.39 µg/ml, respectively. These strains were sensitive to erythromycin. Six of 8 strains of *H. influenzae* were positive for β-lactamase production. The MIC<sub>90</sub> of penicillin-G, ampicillin and sulbactam against 8 strains of *H. influenzae* were 12.5 µg/ml, 3.13 µg/ml, and 1.56 µg/ml, respectively. Most of these penicillin-resistant *S. pneumoniae* (17/18; 94.1%) and β-lactamase producing *H. influenzae* (6/6; 100%) were isolated from HIV-1-infected patients. The MIC<sub>90</sub> of TMP-SMZ against both *S. pneumoniae* and *H. influenzae* was >100 µg/ml. It is obvious that TMP-SMZ can no longer be recommended for treatment of CAP in Uganda.

Among 48 patients with identified pathogens, we could evaluate the clinical effectiveness of antimicrobial therapies primarily consisting of parenteral ampicillin followed by oral amoxicillin for 39 patients with bacterial CAP, because 7 pa-

---

**TABLE 1**

Clinical characteristics of hospitalized patients with community-acquired pneumonia by HIV-status in Uganda

<table>
<thead>
<tr>
<th>HIV-status</th>
<th>HIV-1 infected</th>
<th>HIV-uninfected</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n = 74 (74.8%)</td>
<td>n = 25 (25.2%)</td>
</tr>
</tbody>
</table>

| Age, mean ± SD | 33.2 ± 9.8 | 37.2 ± 21.2 |
| Males, n (%)  | 49 (66.2) | 16 (64.0) |
| Vital signs, n (%) | | |
| Temperature, >38.5°C | 60 (81.1) | 18 (72.0) |
| Respiration rate, >30/min | 44 (59.5) | 13 (52.0) |
| Heart rate, >100/min | 45 (61.7) | 15 (60.0) |
| Hemoglobin, g/dl | 10.5 ± 2.9 | 10.8 ± 2.9 |
| CRP, mg/dl | 8.0 ± 3.2 | 8.0 ± 3.2 |
| Laboratory values, mean ± SD | | |
| WBC, x10³/µl | 11.3 ± 6.0 | 12.9 ± 6.0 |
| CD4 cells/µl | 329.8 ± 285.0 | 876.0 ± 429.0 |
| CD4 cells/µl | 896.0 ± 593.2 | 384.3 ± 239.0 |
| CRP, mg/dl | 0.48 ± 0.46 | 2.60 ± 1.13 |
| CRP, mg/dl | 11.3 ± 2.9 | 12.5 ± 2.4 |
| Hypoxemia, n (%) | 24 (32.4) | 14 (56.0) |
| Pneumothorax, n (%) | 9 (12.2) | 3 (12.0) |
| Oral candidiasis, n (%) | 8 (10.8) | 0 |

NS = not significant.

---

**FIGURE 1.** The distribution of CD4 lymphocyte counts in the peripheral blood in sixty-nine HIV-1-infected patients with community-acquired pneumonia.
tients withdrew from the study before evaluation and two patients with CAP due to *M. tuberculosis* were excluded from evaluation. No significant difference in the percentage of good clinical response between HIV-1-infected and HIV-uninfected patients was observed among these 39 patients (Table 4). An etiologic pathogen in one HIV-uninfected patient with poor clinical response was *K. pneumoniae*. Among 6 HIV-1-infected patients with poor clinical response, etiologic pathogens were *S. pneumoniae* in 3 cases, *K. pneumoniae* in 1 case, *H. influenzae* + *M. catarrhalis* in 1 case and *Enterobacter cloacae* in 1 case. The percentage of good clinical response in HIV-1-infected patients by etiologic agent were 85% (17/20) in *S. pneumoniae* as causative pathogens of community-acquired pneumonia (75%) among hospitalized adult patients with CAP. This rate was three- to four-fold higher than the recently reported HIV-1 seroprevalence in people attending the AIDS Information Centre or women attending antenatal clinics in Kampala,22,23 A high HIV seroprevalence among patients with acute respiratory illness was already reported in Burundi (54%) and Tanzania (74%). These data indicate a high HIV seroprevalence rate among the general population of the other countries in Central and East Africa.4,5 The CD4 lymphocyte counts in approximately three-fourths of the HIV-infected patients in this study were almost equally distributed less than 400/µl whereas they were clustered in the group with CD4 less than 100/µl in a previous study of US patients.6 HIV-infected persons in sub-Saharan Africa may, therefore, be at risk for CAP even in the early stage of HIV infection. The present clinical and labora-
Among bacterial pathogens identified in HIV-1-infected patients, we found not only S. pneumoniae (31%), but also H. influenzae (12%) and M. catarrhalis (11%), although only a few of these strains had been identified as pathogens in previous studies in Africa.12,13 In our present study, a high isolation rate of H. influenzae could be explained by the quantitative culture method using rabbit blood agar, which is highly sensitive for this microorganism.68 Distribution of bacterial etiology for CAP among HIV-1-infected persons was similar to those in the US.14 The mean CD4 counts among HIV-1-infected patients with CAP due to S. aureus or M. tuberculosis were much lower than those due to major bacterial pathogens such as S. pneumoniae, H. influenzae or M. catarrhalis. These data support the view that S. aureus is a causative pathogen of pneumonia in HIV-infected persons with an advanced stage of immunosuppression.24 We have similarly documented that the CD4 peripheral-blood lymphocyte counts of the majority of patients with pulmonary tuberculosis and HIV-1 infection in Uganda were less than 200/μL.24 A few cases of CAP due to M. pneumoniae or C. pneumoniae were reported in a study in Cameroon.15 We, however, did not find a four-fold rise of antibody titer for these pathogens in the present study. Previous studies have reported Pneumocystis carinii (P. carinii) pneumonia is uncommon in HIV-infected individuals in sub-Saharan Africa,12,13,30 although P. carinii is a commonly identified etiologic agent of AIDS-associated CAP in the US.43 We also did not encounter cases suspected to be due to P. carinii by clinical and radiological manifestations such as tachypnea and reticulonodular shadows during the short period of follow-up in this study.26 Recent studies, however, have reported a relatively high frequency of P. carinii pneumonia in African patients with AIDS.26,27 The diagnostic procedures employing induced sputum or bronchoalveolar lavage with special staining performed on the specimens and longer follow-up for CAP patients with low CD4 lymphocyte counts are also necessary to exclude P. carinii pneumonia in sub-Saharan Africa.28

Recent studies indicated the successful treatment by short-term parenteral β-lactam antibiotics prior to an oral switch for hospitalized patient with uncomplicated CAP.10,11 In India, investigators reported that all patients with CAP responded to one week of parental penicillin followed by oral antibiotics, with a total therapy duration of 10 days.26 No study, however, has evaluated the usefulness of short-term parenteral antibiotic therapy for CAP in HIV-infected individuals, especially in developing countries. In this study, more than 80% of the patients had good clinical response by short-term parenteral ampicillin followed by oral amoxicillin in both HIV-1-infected and HIV-uninfected patients with bacterial CAP. No difference in the percentage of good clinical response between HIV-1-infected and HIV-uninfected patients was observed, although the number of HIV-uninfected patients was small. The low dose of ampicillin, however, may be insufficient to eradicate pathogens in HIV-infected patients with low CD4 lymphocyte counts. We are now developing a study to determine whether higher doses of parenteral ampicillin are more effective.

In this study, we documented a high frequency (95%) of penicillin resistance in S. pneumoniae. Penicillin resistance in S. pneumoniae isolated from HIV-infected patients with pneumonia has been reported in Kenya and France,29,30 although the frequency of penicillin resistance was still low (17–31%) in these areas. However, a few cases of clinically observed treatment failure by β-lactam antibiotics in pneumonia due to PRSP have been reported despite an epidemic of PRSP.11,32 We found only three cases of treatment failure for CAP due to PISP (two cases) and PRSP (one case) by short-term parenteral ampicillin therapy despite a very high frequency of penicillin-resistance in isolated S. pneumoniae strains. In addition, the rate of β-lactamase production in H. influenzae (75%) in our study was also higher than that in other parts of the world.28,34 Subsequently, only one case of treatment failure in CAP due to β-lactamase producing H. influenzae was noted. The tissue levels of ampicillin appeared to be higher than the MIC levels of ampicillin against these organisms in most CAP cases.35 To our knowledge, this study is the first report of a short-term parenteral antibiotic therapy for CAP in developing countries where PRSP and β-lactamase producing H. influenzae are prevalent.

The present data support the usefulness of short-term parenteral ampicillin therapy followed by oral amoxicillin for patients with bacterial CAP both in HIV-1-infected and HIV-uninfected patients. Treatment failures in cases of CAP due to penicillin-resistant bacterial pathogens and due to unknown etiology, especially in HIV-infected patients, indicate that careful etiologic diagnosis and targeted antimicrobial treatment is important. Further investigation of diagnostic etiologies and clinical effectiveness of short-term parenteral ampicillin therapy prior to an oral switch is required in order to provide proper guidelines for treatment of CAP in developing countries where HIV infection is common.

Acknowledgments: The authors thank Ococi-Jungala and W. Muzawu for their technical support and S. Nadigire, S. Nansikombi, A. Margret, and I. Serwanga for their patient management. We are grateful to K. Matsumoto and B. W. Nielsen for their critical comments on this study.

Financial support: This work was supported, in part, by a grant from the Ministry of Education, Science and Culture, and from the Japan-US Cooperative Medical Sciences Program on Acute Respiratory Infections and International Cooperation Grant from the Ministry of Health and Welfare, Japan.

Authors’ addresses: Hiroyuki Yoshimine, Kazunori Oshii, Hidehiko Takahashi, Hideaki Amano, Kiwao Watanabe, Kamrardin Ahmed, Masaaki Shimada, and Tsuyoshi Nagatake, Department of Internal Medicine and Information and Reference Center, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan. Francis Mubiru, Hawa Nalwoga, Philip Ombabi, Moses Joloba, Thomas Asu, and Roy Mugerwa, Department of Medicine and Microbiology, Makerere University, Kampala, Uganda.

Reprint requests: Hiroyuki Yoshimine, Department of Internal Medicine, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.


